| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 3/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
AVNS Stock Overview
Avanos Medical, Inc. operates as a medical technology company that focuses on delivering medical device solutions to improve patients’ quality of life in North America, Europe, the Middle East, Africa, the Asia Pacific, and Latin America.
Rewards
Risk Analysis
No risks detected for AVNS from our risk checks.
Avanos Medical Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$31.82 |
| 52 Week High | US$53.61 |
| 52 Week Low | US$28.95 |
| Beta | 0.88 |
| 1 Month Change | -6.11% |
| 3 Month Change | 0.86% |
| 1 Year Change | -33.22% |
| 3 Year Change | -28.53% |
| 5 Year Change | -17.29% |
| Change since IPO | -19.95% |
Recent News & Updates
Should You Think About Buying Avanos Medical, Inc. (NYSE:AVNS) Now?
While Avanos Medical, Inc. ( NYSE:AVNS ) might not be the most widely known stock at the moment, it saw a double-digit...
Shareholder Returns
| AVNS | US Medical Equipment | US Market | |
|---|---|---|---|
| 7D | 0.5% | -4.3% | -5.1% |
| 1Y | -33.2% | -3.7% | 3.3% |
Return vs Industry: AVNS underperformed the US Medical Equipment industry which returned -2.1% over the past year.
Return vs Market: AVNS underperformed the US Market which returned 4.2% over the past year.
Price Volatility
| AVNS volatility | |
|---|---|
| AVNS Average Weekly Movement | 6.2% |
| Medical Equipment Industry Average Movement | 8.5% |
| Market Average Movement | 6.7% |
| 10% most volatile stocks in US Market | 15.4% |
| 10% least volatile stocks in US Market | 2.4% |
Stable Share Price: AVNS is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 6% a week.
Volatility Over Time: AVNS's weekly volatility (6%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2014 | 5,380 | Joe Woody | https://avanos.com |
Avanos Medical, Inc. operates as a medical technology company that focuses on delivering medical device solutions to improve patients’ quality of life in North America, Europe, the Middle East, Africa, the Asia Pacific, and Latin America. It offers a portfolio of chronic care products that include digestive health products, such as Mic-Key enteral feeding tubes, Corpak patient feeding solutions, and NeoMed neonatal and pediatric feeding solutions; and respiratory health products, such as closed airway suction systems and other airway management devices under the Ballard, Microcuff, and Endoclear brands. The company also provides a portfolio of non-opioid pain solutions, including acute pain products, such as On-Q and ambIT surgical pain pumps and Game Ready cold and compression therapy systems; and interventional pain solutions, which offers minimally invasive pain relieving therapies, such as Coolief pain relief therapy.
Avanos Medical Fundamentals Summary
| AVNS fundamental statistics | |
|---|---|
| Market Cap | US$1.52b |
| Earnings (TTM) | -US$52.00m |
| Revenue (TTM) | US$736.20m |
2.1x
P/S Ratio-29.3x
P/E RatioIs AVNS overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| AVNS income statement (TTM) | |
|---|---|
| Revenue | US$736.20m |
| Cost of Revenue | US$357.90m |
| Gross Profit | US$378.30m |
| Expenses | US$430.30m |
| Earnings | -US$52.00m |
Last Reported Earnings
Sep 30, 2021
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.09 |
| Gross Margin | 51.39% |
| Net Profit Margin | -7.06% |
| Debt/Equity Ratio | 11.5% |
How did AVNS perform over the long term?
See historical performance and comparisonValuation
Is Avanos Medical undervalued compared to its fair value and its price relative to the market?
39.7%
Undervalued compared to fair value
Share Price vs. Fair Value
Below Fair Value: AVNS ($31.82) is trading below our estimate of fair value ($52.75)
Significantly Below Fair Value: AVNS is trading below fair value by more than 20%.
Price To Earnings Ratio
PE vs Industry: AVNS is unprofitable, so we can't compare its PE Ratio to the US Medical Equipment industry average.
PE vs Market: AVNS is unprofitable, so we can't compare its PE Ratio to the US market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate AVNS's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: AVNS is good value based on its PB Ratio (1.2x) compared to the US Medical Equipment industry average (3.3x).
Future Growth
How is Avanos Medical forecast to perform in the next 1 to 3 years based on estimates from 5 analysts?
68.8%
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: AVNS is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (2%).
Earnings vs Market: AVNS is forecast to become profitable over the next 3 years, which is considered above average market growth.
High Growth Earnings: AVNS's is expected to become profitable in the next 3 years.
Revenue vs Market: AVNS's revenue (5.6% per year) is forecast to grow slower than the US market (9.1% per year).
High Growth Revenue: AVNS's revenue (5.6% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: AVNS's Return on Equity is forecast to be low in 3 years time (6%).
Past Performance
How has Avanos Medical performed over the past 5 years?
24.1%
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: AVNS is currently unprofitable.
Growing Profit Margin: AVNS is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: AVNS is unprofitable, but has reduced losses over the past 5 years at a rate of 24.1% per year.
Accelerating Growth: Unable to compare AVNS's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: AVNS is unprofitable, making it difficult to compare its past year earnings growth to the Medical Equipment industry (51.2%).
Return on Equity
High ROE: AVNS has a negative Return on Equity (-4.12%), as it is currently unprofitable.
Financial Health
How is Avanos Medical's financial position?
Financial Position Analysis
Short Term Liabilities: AVNS's short term assets ($405.0M) exceed its short term liabilities ($129.2M).
Long Term Liabilities: AVNS's short term assets ($405.0M) exceed its long term liabilities ($206.8M).
Debt to Equity History and Analysis
Debt Level: AVNS's net debt to equity ratio (3.7%) is considered satisfactory.
Reducing Debt: AVNS's debt to equity ratio has reduced from 53.5% to 11.5% over the past 5 years.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: Whilst unprofitable AVNS has sufficient cash runway for more than 3 years if it maintains its current positive free cash flow level.
Forecast Cash Runway: AVNS is unprofitable but has sufficient cash runway for more than 3 years, even with free cash flow being positive and shrinking by 34.5% per year.
Dividend
What is Avanos Medical current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate AVNS's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate AVNS's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if AVNS's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if AVNS's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of AVNS's dividend in 3 years as they are not forecast to pay a notable one for the US market.
Next Steps
Management
How experienced are the management team and are they aligned to shareholders interests?
2.0yrs
Average management tenure
CEO
Joe Woody (55 yo)
4.58yrs
Tenure
US$7,550,730
Compensation
Mr. Joseph F. Woody, also known as Joe, has been Chief Executive Officer and Director of Avanos Medical, Inc. (formerly known as Halyard Health, Inc.) since June 26, 2017. Mr. Woody served as the Chief Exe...
CEO Compensation Analysis
Compensation vs Market: Joe's total compensation ($USD7.55M) is above average for companies of similar size in the US market ($USD3.74M).
Compensation vs Earnings: Joe's compensation has increased whilst the company is unprofitable.
Leadership Team
Experienced Management: AVNS's management team is considered experienced (2 years average tenure).
Board Members
Experienced Board: AVNS's board of directors are considered experienced (7.3 years average tenure).
Ownership
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Ownership Breakdown
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Top Shareholders
Company Information
Avanos Medical, Inc.'s employee growth, exchange listings and data sources
Key Information
- Name: Avanos Medical, Inc.
- Ticker: AVNS
- Exchange: NYSE
- Founded: 2014
- Industry: Health Care Supplies
- Sector: Healthcare
- Implied Market Cap: US$1.522b
- Shares outstanding: 47.84m
- Website: https://avanos.com
Number of Employees
Location
- Avanos Medical, Inc.
- 5405 Windward Parkway
- Suite 100 South
- Alpharetta
- Georgia
- 30004
- United States
Listings
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2022/01/26 01:08 |
| End of Day Share Price | 2022/01/25 00:00 |
| Earnings | 2021/09/30 |
| Annual Earnings | 2020/12/31 |
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.